Summit Microelectronics Inc., a Sunnyvale, Calif.-based provider of programmable power management ICs, has raised $10 million in Series G funding. Nokia Growth Partners led the deal with a $4 million infusion, and was joined by return backers Norwest Venture Partners, August Capital, Pequot Ventures, Bessemer Venture Partners and Hotung Capital Management. www.summitmicro.com
Trigence Corp., a Jersey City, N.J. and Ottawa-based provider of applications software for IT operations, has raised $8 million in second-round funding. GrowthWorks led the deal, and was joined by return backers BDC Venture Capital and VenGrowth Capital Partners. www.trigence.com
Q-layer, a Belgium-based provider of datacenter solutions, has raised
Meraki Networks, a Mountain View, Calif.-based developer of wireless mesh hardware and software, has raised $5.86 million in Series A funding led by Sequoia Capital. www.meraki.net
CoreLogic Systems Inc., a Sacramento, Calif.-based provider of mortgage risk assessment and fraud prevention solutions, has merged with The First American Corp. (NYSE: FAF). The combined entity is majority owned by First American Corp. via its FARES LLC joint venture with Experian Group, while CoreLogic shareholders
Specialty European Pharma Ltd., a UK-based drug commercialization company, has raised
Burger King Holdings Inc. (NYSE: BKC) has filed for a secondary public offering of 20 million shares. Selling stockholders include Bain Capital (6.4 million shares offered), Goldman Sachs (6.4 million) and Texas Pacific Group (7.2 million). The three firms will still hold more than a 60% stake in the company, post-offering. www.bk.com
Levine Leichtman Capital Partners has retained North Point Advisors to help it sell pizza chain operator CiCi Enterprises, according to LBO Wire. The asking price is expected to be between $240 million and $270 million.
Anacor Pharmaceuticals Inc. of Palo Alto, Calif. has entered into an agreement with Schering-Plough Corp. for the development and commercialization of AN2690, a topical anti-fungal therapy currently in Phase 2 clinical trials for onychomycosis, a fungal infection of the nail and nail bed. Under terms of the agreement, Anacor will receive a $40 million upfront […]
Boston Ventures is raising up to $500 million for its seventh private equity fund, according to a regulatory filing. It already has secured around $200 million in capital commitments. www.bostonventures.com